2 billion varieties Hengrui, Yangzijiang listed at the same time

Medicines Network June 4Hengrui, Yangzijiang at the same time listed, over the evaluationJune 1, the StateDrug
administration government service portal updated the drug approval documents to receive information, HengruiPharmaceuticaland Yangzijiang Pharmaceutical's Jifeitini tablets were approved for listing, because of its new 4 generic drug declaration, as a result of the consistent evaluationpublic information shows that gifitinib is an oral epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor (a small molecular compound), inhibited eGFR-TK can hinder tumor growth, metastasis and angiogenesis, and increase tumor cell apoptosisGiofini's original pharmaceutical company for AstraZeneca, in 2005 the original research drug (Irisa) listed in china, the price is 5000 yuan / box, AstraZeneca through national negotiations, the price from 5000 yuan to 2358 yuan, a decline of more than 2/3In the first round of band procurement, AstraZeneca became the first major pharmaceutical companies with the winning bid, and finally won the price of 547 yuan, a decline of more than 76%In September 2019, Qilu Pharmaceuticals, Zhengda Tianqing and AstraZeneca's threecompanies257 yuan, 450 yuan and 547 yuan a box (10 tablets / 25 mg) respectivelySeiber Blue in the Minet database query learned that in 2019 China's publichospitalsterminal, Giferitini reached 2.18 billion sales, a slight decline from 2018, or due to the impact of the national expansion - although the volume is guaranteed, but the sharp price reduction led to the overall decline in sales, sales growth in 2019 to negative value, a decline of 7.51%market share battle, generic drugs to promote price reduction the earliest, in the domestic Giifitinib on the eve of the listing, AstraZeneca through the national negotiations to reduce the price from 5000 yuan to 2,358 yuan 　　The impact of domestic generic drugs on the original drug is not only in the price reduction, but another competition for market share According to Ameda data, Ziru Pharmaceuticals took a 9% market share in AstraZeneca in 2017 after it was approved for the market in 2016 　　Zhengda Isan also came out in May 2019 to join the competition 　　On May 21, China Biopharmaceutical Co., Ltd announced that its subsidiary Zhengda Tianqing Pharmaceutical Group Co., Ltd developed the anti-tumor drug gibutinib tablets have been issued by the State Drug Administration of the People's Republic of China for drug registration approval 　　The battle for market share is back on the up again 　　Cypress Blue in the mine net query giofini data, in 2019 the domestic variety market share has been three co-occupied, AstraZeneca market fell to 74.96 percent, Qilu Pharmaceuticals market from the original 9 percent to 23.56 percent, and Zhengda Tianqing also quickly won 1.48 percent of the market share the largest variable of the species, it is the national collection 　　In the second round of national collection and expansion, Qilu Pharmaceuticals, Zhengda Tianqing and AstraZeneca three enterprises were selected for 257 yuan, 450 yuan and 547 yuan a box (10 tablets /25 mg) respectively In accordance with the relevant provisions, the actual selection of enterprises for 3, agreed to procurement for the first year agreed to the procurement volume calculation base of 70%, three provinces selected in order, roughly divided equally The amount of purchase agreed in the following year shall in principle be not less than the agreed purchase quantity in the first year of the selected variety 　　With the landing of the national collection and expansion, Zhengda sun will quickly seize the relevant market, market share to further enhance 　　Giifitini, the procurement completion rate is low
in the end the national collection can bring about a variety of market expansion of how much impact? 　　Recently, Jiangxi Province issued the implementation of the national organization of centralized procurement of drugs and the use of pilot expansion of the work of the briefing, online procurement The left-wing Eracetam finished more than expected, reaching 400.47%, but Gifitini had the lowest completion rate, at 23.21% 　　In this regard, Yanjiang Pharmaceutical Marketing Director Huang Yong once said to Cypress Blue: On the one hand, the control fee of cancer drugs is not high, the supply is limited to be relatively small; 　　Based on existing estimates, the remaining three quarters are on schedule and 100 per cent of the report should be completed within a year 　　Qilu Pharmaceuticals is da Tianqing Pharmaceutical Group and Hunan Koren Pharmaceuticals and other products have been reviewed (or regarded as a review), Insight database shows that in addition to the five approved generic drugs, there are nanjing Yuke, Tianshili, Shanghai Chongno, Suzhou Teri and other 7 companies in the generic drug listed, including NATCO Pharmaceuticals imported generic drugs 　　Yesterday, Hengrui and Yangzijiang two pharmaceutical giants were approved for listing at the same time, as if through a consistent evaluation, or will further eat into the market share of the original research drug - after all, the sales capacity of both can not be underestimated